{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-281143","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2026-06-24T20:31:58+00:00","discovered_at":"2026-06-24T20:33:00.346607+00:00","generated_at":"2026-06-24T20:33:17.610715+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Absci prices $100M common stock offering at $7.41/share; Lilly, other investors participate","bullets":["13,495,277 shares priced at $7.41 each; gross proceeds ~$100M, net ~$93.5M after fees.","Offering includes participation from Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile.","Net proceeds to fund AI-designed anti-PRLR antibody ABS-201 for alopecia and endometriosis.","Offering expected to close June 25, 2026; Jefferies, J.P. Morgan, TD Cowen, Guggenheim as bookrunners.","Shares sold under effective shelf registration statement (File No. 333-289541)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-281143","json":"https://secwatch.observer/filing/0001193125-26-281143.json","markdown":"https://secwatch.observer/filing/0001193125-26-281143.md","text":"https://secwatch.observer/filing/0001193125-26-281143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/0001193125-26-281143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000119312526281143/d139233d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T20:33:17.610715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}